EPCAM and hepatocellular carcinoma: To examine the impact of p38 MAPK activation on tumor-initiating HCC cells, we conducted sphere formation assays on EpCAM+ HCC cells treated with DSF and/or SB203580, a specific inhibitor of p38 (Figure 4A).